Skip to content
ClinCalc Pro
Menu
Atypical Antipsychotic — D2/5-HT2A Antagonist (Low Metabolic Risk)

Ziprasidone

Brand names: Geodon, Zeldox

Ziprasidone is a second-generation (atypical) antipsychotic used in the management of schizophrenia and bipolar disorder.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It antagonises dopamine D2 and serotonin 5-HT2A receptors, with additional activity at other serotonergic and adrenergic receptors contributing to its effect.

Prescribing in practice

  • It can prolong the QT interval, so it is contraindicated in those with known QT prolongation, recent myocardial infarction or uncompensated heart failure, and caution is needed with other QT-prolonging drugs.
  • Oral absorption is substantially enhanced when taken with food, so consistency in administration is important.
  • Use with caution in those with risk factors for electrolyte disturbance, which can potentiate arrhythmia risk.

Monitoring

Monitor ECG where there are cardiac risk factors, along with electrolytes, weight and metabolic parameters.

Counselling the patient

  • Take the medicine with food to ensure it is absorbed properly.
  • Report palpitations, fainting or dizziness without delay.
  • Do not stop treatment suddenly without discussing it with your prescriber.

Evidence & guidelines

Atypical antipsychotics are established options for schizophrenia, with choice guided by side-effect profile per NICE guidance.

Reference: Lieberman et al. NEJM 2005 (CATIE trial); BAP Guidelines for Schizophrenia; MHRA SPC Zeldox/Geodon; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.